文献速递消化内镜消化道肿瘤与早癌炎症性肠病

系统综述与荟萃分析:按世界内镜组织方法学计算的结肠镜检查后结直肠癌三年发生率

Systematic Review and Meta-analysis: The Three-year Post-colonoscopy Colorectal Cancer Rate as per the World Endoscopy Organization Methodology.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-27

该研究系统检索5个数据库至2024年1月,纳入8项严格遵循世界内镜组织(WEO)方法学的研究,共220,106例检出结直肠癌和18,148例结肠镜检查后结直肠癌(PCCRC),2002至2017年间。西方世界PCCRC三年合并发生率为7.5%(95%CI 6.4%-8.7%),从2006年的7.9%显著下降至2012年的6.7%(OR 0.79,95%CI 0.72-0.87)。炎症性肠病、既往结直肠癌、近端结直肠癌、憩室病和女性与PCCRC发生率升高相关。

要点

  • 西方世界PCCRC三年合并发生率为7.5%(95%CI 6.4%-8.7%)。
  • PCCRC三年发生率从2006年7.9%降至2012年6.7%(OR 0.79,95%CI 0.72-0.87)。
  • 炎症性肠病者PCCRC三年发生率29.3%(OR 6.17,95%CI 4.73-8.06)。

核心结论

  • 按WEO方法学,西方世界PCCRC三年发生率为7.5%,随时间下降,但需进一步工作以明确PCCRC原因,尤其是高风险人群。
  • 作者设计了WEO方法学清单以提高其采用率并标准化未来PCCRC-3yr研究中的患者分类。

研究设计与样本

  • 系统综述与荟萃分析,检索5个数据库自建库至2024年1月,纳入严格遵循WEO方法学的PCCRC-3yr研究。
  • 纳入8项来自4个西欧和2个北美国家的研究,共220,106例检出结直肠癌和18,148例PCCRC,时间范围为2002至2017年。

主要发现

  • 西方世界PCCRC三年合并发生率为7.5%(95%CI 6.4%-8.7%)。
  • PCCRC三年发生率从2006年的7.9%(95%CI 6.6%-9.4%)显著下降至2012年的6.7%(95%CI 6.1%-7.3%)(P<.05;OR 0.79,95%CI 0.72-0.87)。
  • 炎症性肠病者PCCRC三年发生率为29.3%(OR 6.17,95%CI 4.73-8.06)。
  • 既往结直肠癌者PCCRC三年发生率为29.8%(OR 3.03,95%CI 1.34-4.72)。
  • 近端结直肠癌者PCCRC三年发生率为8.6%(OR 1.51,95%CI 1.41-1.61)。

关键数值与推荐

  • 憩室病者PCCRC三年发生率为11.6%(OR 1.74,95%CI 1.37-2.10)。
  • 女性PCCRC三年发生率为7.9%(OR 1.15,95%CI 1.11-1.20)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • Several studies failed to adhere to the WEO methodology. 若干研究未能遵循WEO方法学。
  • further work is required to identify the reasons for PCCRCs, especially in higher-risk groups. 需进一步工作以明确PCCRC原因,尤其是高风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In 2018, the World Endoscopy Organization (WEO) introduced standardized methods for calculating post-colonoscopy colorectal cancer-3yr rates (PCCRC-3yr). This systematic review aimed to calculate the global PCCRC-3yr according to the WEO methodology, its change over time, and to measure the association between risk factors and PCCRC occurrences. METHODS: We searched 5 databases from inception until January 2024 for PCCRC-3yr studies that strictly adhered to the WEO methodology. The overall pooled PCCRC-3yr was calculated. For risk factors and time-trend analyses, the pooled PCCRC-3yr and odds ratios (ORs) of subgroups were compared. RESULTS: Several studies failed to adhere to the WEO methodology. Eight studies from 4 Western European and 2 Northern American countries were included, totalling 220,106 detected-colorectal cancers (CRCs) and 18,148 PCCRCs between 2002 and 2017. The pooled Western World PCCRC-3yr was 7.5% (95% confidence interval [CI], 6.4%-8.7%). The PCCRC-3yr significantly (P < .05) decreased from 7.9% (95% CI, 6.6%-9.4%) in 2006 to 6.7% (95% CI, 6.1%-7.3%) in 2012 (OR, 0.79; 95% CI, 0.72-0.87). There were significantly higher rates for people with inflammatory bowel disease (PCCRC-3yr, 29.3%; OR, 6.17; 95% CI, 4.73-8.06), prior CRC (PCCRC-3yr, 29.8%; OR, 3.03; 95% CI, 1.34-4.72), proximal CRC (PCCRC-3yr, 8.6%; OR, 1.51; 95% CI, 1.41-1.61), diverticular disease (PCCRC 3-yr, 11.6%; OR, 1.74; 95% CI, 1.37-2.10), and female sex (PCCRC-3yr, 7.9%; OR, 1.15; 95% CI, 1.11-1.20). CONCLUSION: According to the WEO methodology, the Western World PCCRC-3yr was 7.5%. Reassuringly, this has decreased over time, but further work is required to identify the reasons for PCCRCs, especially in higher-risk groups. We devised a WEO methodology checklist to increase its adoption and standardise the categorization of patients in future PCCRC-3yr studies.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kader R, Hadjinicolaou AV, Burr NE, et al. Systematic Review and Meta-analysis: The Three-year Post-colonoscopy Colorectal Cancer Rate as per the World Endoscopy Organization Methodology. Clin Gastroenterol Hepatol. 2024. PMID: 39209191. doi:10.1016/j.cgh.2024.07.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。